Paul R. Kirchgraber - Mar 30, 2023 Form 4 Insider Report for LABORATORY CORP OF AMERICA HOLDINGS (LH)

Role
CEO, Covance Drug Development
Signature
/s/ Sandra van der Vaart, Attorney-in-Fact for Paul R. Kirchgraber
Stock symbol
LH
Transactions as of
Mar 30, 2023
Transactions value $
-$648,484
Form type
4
Date filed
4/3/2023, 10:13 AM
Previous filing
Feb 23, 2023
Next filing
May 23, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LH Common Stock Award $0 +6.76K +74.57% $0.00 15.8K Mar 30, 2023 Direct F1
transaction LH Common Stock Tax liability -$648K -2.89K -18.23% $224.70 12.9K Mar 30, 2023 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares acquired on March 30, 2023, pursuant to a performance award granted on February 4, 2020, relating to performance during the three-year period ended December 31, 2022.
F2 Stock withholding to satisfy tax withholding obligations.